tadalafil has been researched along with Alloxan Diabetes in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, Y; Inamura, S; Ito, H; Kobayashi, H; Nagase, K; Taga, M; Yokoyama, O; Zha, X | 1 |
| Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L | 1 |
| Aizawa, N; Fukuhara, H; Igawa, Y; Kume, H; Masuda, K; Okegawa, T; Watanabe, D | 1 |
| Aoki, K; Fujimoto, K; Gotoh, D; Hirayama, A; Hori, S; Miyake, M; Morizawa, Y; Tanaka, N; Tatsumi, Y; Torimoto, K; Yamada, A | 1 |
| Fujimoto, K; Gotoh, D; Hirayama, A; Hori, S; Iwamoto, T; Iwasaki, H; Miyake, M; Morizawa, Y; Nishi, E; Tanaka, N; Torimoto, K | 1 |
| Angulo, J; Chen, M; Cuevas, P; Fernández, A; González-Corrochano, R; La Fuente, J; Sáenz de Tejada, I | 1 |
| Mostafa, ME; Mostafa, T; Senbel, AM | 2 |
| Frauscher, F; Pingerra, GM | 1 |
| Abdel Aziz, MT; Ahmed, HH; Atta, HM; Fouad, H; Rezq, AM; Sabry, D; Yehia, HM; Zaahkouk, AM | 1 |
| Chopp, M; Jia, L; Lu, M; Lu, X; Szalad, A; Wang, L; Zhang, RL; Zhang, ZG | 1 |
| Kotb, K; Mostafa, T; Rashed, L; Taymour, M | 1 |
| Chen, Y; Dai, YT; Gao, J; Li, XX; Lin, HC; Qiu, XF; Wang, R | 1 |
| Das, A; Durrant, DE; Hoke, NN; Kukreja, RC; Salloum, FN; Varma, A | 1 |
| Das, A; Koka, S; Kukreja, RC; Salloum, FN | 1 |
1 review(s) available for tadalafil and Alloxan Diabetes
| Article | Year |
|---|---|
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hydroxychloroquine; Hyperglycemia; Insulin Resistance; Male; Mice; Myocardial Infarction; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2023 |
14 other study(ies) available for tadalafil and Alloxan Diabetes
| Article | Year |
|---|---|
Phosphodiesterase 5 inhibitor suppresses prostate weight increase in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin-Like Growth Factor I; Male; Phosphodiesterase 5 Inhibitors; Prostate; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Tadalafil; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Weight Gain | 2022 |
Pathophysiological changes of the lower urinary tract behind voiding dysfunction in streptozotocin-induced long-term diabetic rats.
Topics: Animals; Arginine; Diabetes Mellitus, Experimental; Male; Rats; Rats, Wistar; Residual Volume; Streptozocin; Tadalafil; Urinary Bladder | 2020 |
Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Female; Lower Urinary Tract Symptoms; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Tadalafil; Urethra; Urinary Bladder | 2018 |
Tadalafil, a phosphodiesterase type 5 inhibitor, restores urethra and detrusor function in the initial phase of diabetes in rats.
Topics: Animals; Carbachol; Diabetes Mellitus, Experimental; Electric Stimulation; Female; Muscle Contraction; Muscle, Smooth; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Tadalafil; Urethra; Urinary Bladder | 2019 |
Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.
Topics: Adult; Aged; Animals; Benzimidazoles; Carbolines; Cyclic GMP; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Erectile Dysfunction; Humans; Male; Middle Aged; Nitric Oxide; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Potassium Channels, Calcium-Activated; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilation; Vasodilator Agents | 2013 |
Effect of chronic low-dose tadalafil on penile cavernous tissues in diabetic rats.
Topics: Animals; Capillaries; Carbolines; Diabetes Mellitus, Experimental; Elastic Tissue; Male; Microscopy, Electron; Muscle, Smooth, Vascular; Nerve Fibers; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Rats; Tadalafil | 2013 |
Reply: To PMID 23726447.
Topics: Animals; Carbolines; Diabetes Mellitus, Experimental; Male; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Tadalafil | 2013 |
Editorial comment.
Topics: Animals; Carbolines; Diabetes Mellitus, Experimental; Male; Penile Erection; Penis; Phosphodiesterase 5 Inhibitors; Tadalafil | 2013 |
Molecular signalling of a novel curcumin derivative versus Tadalafil in erectile dysfunction.
Topics: Animals; Curcumin; Cyclic GMP; Diabetes Mellitus, Experimental; Erectile Dysfunction; Heme Oxygenase-1; Male; NF-E2-Related Factor 2; NF-kappa B; Nitric Oxide Synthase; p38 Mitogen-Activated Protein Kinases; Penis; Phosphodiesterase 5 Inhibitors; Rats; Tadalafil | 2015 |
Tadalafil Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Models, Animal; Gene Expression Regulation; Humans; Lymphokines; Mice; Mice, Inbred NOD; Motor Activity; Nerve Fibers; Nerve Growth Factor; Peripheral Nervous System Diseases; Platelet-Derived Growth Factor; Sciatic Nerve; Tadalafil | 2016 |
Effect of testosterone and frequent low-dose sildenafil/tadalafil on cavernous tissue oxidative stress of aged diabetic rats.
Topics: Aging; Animals; Carbolines; Cyclic GMP; Diabetes Mellitus, Experimental; Erectile Dysfunction; Glutathione Peroxidase; Male; Malondialdehyde; Oxidative Stress; Penile Erection; Penis; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Tadalafil; Testosterone; Vasodilator Agents | 2012 |
The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanism.
Topics: Animals; Antioxidants; Blood Pressure; Carbolines; Diabetes Mellitus, Experimental; Erectile Dysfunction; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Muscle; Penis; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Streptozocin; Superoxide Dismutase; Tadalafil | 2012 |
Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Mellitus, Experimental; Drug Administration Schedule; Fasting; Interleukin-1beta; Male; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Necrosis; Obesity; Phosphodiesterase Inhibitors; Receptors, Leptin; Tadalafil; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice.
Topics: Animals; Apoptosis; Carbolines; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Mice; Mitochondria, Heart; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nitric Oxide; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Reactive Oxygen Species; Tadalafil | 2013 |